Critical remote exploit in widely used Oracle Fusion Middleware SDP enabling full data compromise and service disruption across enterprise deployments.
CVE-2026-60377
Critical remote vulnerability in Oracle Fusion Middleware SDP enabling full data compromise.
Is CVE-2026-60377 being exploited?
Not confirmed. CVE-2026-60377 does not appear in CISA's Known Exploited Vulnerabilities catalog, which records only exploitation that has been observed and reported publicly. That is evidence of absence of a report, not evidence the flaw is unattacked. EPSS currently estimates a 0.39% probability of exploitation in the next 30 days.
How severe is CVE-2026-60377?
CVE-2026-60377 is rated Critical with a CVSS score of 9.9. Severity describes how bad exploitation would be, not how likely it is: pair it with exploitation evidence before deciding what to patch first.
Is there a patch for CVE-2026-60377?
Yes. A fix has been recorded for CVE-2026-60377. The vendor advisory is the authority on the exact fixed version — apply it from there rather than from a summary.
What does CVE-2026-60377 affect?
CVE-2026-60377 affects Oracle Fusion Middleware Service Delivery Platform (Messaging Enabler) 12.2.1.4.0, Oracle Fusion Middleware Service Delivery Platform (Messaging Enabler) 14.1.2.0.0. Confirm the exact affected versions against the vendor advisory before deciding you are exposed.
What should I do about CVE-2026-60377?
Apply vendor patch/mitigations; block/restrict T3/IIOP, isolate SDP, and monitor logs.
Exploitation status reflects CISA's KEV catalog as we last synced it. Check the catalog directly.
Remote low-priv attacker via T3/IIOP can create/modify/delete data, gain full access to SDP data, and cause partial DoS.
Immediate action required
- affected12.2.1.4.0
- affected14.1.2.0.0
As published in the CVE Program record. A version outside these ranges is not a statement that it is unaffected — vendors sometimes understate a range, and distribution-backported builds carry upstream numbers that do not reflect what was patched into them.